STOCK TITAN

Praxis Precision Medicines, Inc. - $PRAX STOCK NEWS

Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: $PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Praxis Precision Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Praxis Precision Medicines's position in the market.

Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) will host a virtual program update to discuss its PRAX-628 program in epilepsy on March 26, 2024. The event will feature key opinion leader Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.13%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. reports strong progress in various clinical studies for CNS disorders, including essential tremor and epilepsy. They have received over 3,000 referrals for ulixacaltamide Phase 3 studies and expect topline results by 2024. The PRAX-628 study in epilepsy patients showed promising preliminary results. Additionally, the EMBRAVE study of elsunersen demonstrated a 43% median reduction in seizures and received PRIME designation from the EMA. Praxis also announced a licensing partnership with Tenacia Biotechnology for ulixacaltamide development in Greater China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) will participate in the TD Cowen 44th Annual Health Care Conference in Boston from March 4 – 6, 2024. The company will engage in one-on-one investor meetings and a corporate panel discussion on orphan epilepsies. The webcast of the panel discussion will be available on the company's website for 90 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
conferences
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) granted non-qualified stock options and restricted stock units to new non-executive employees under the 2024 Inducement Plan. The options have an exercise price of $43.73 per share and will vest over four years, while the restricted stock units will vest in four equal annual installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced the pricing of its underwritten public offering of 3,168,275 shares of its common stock at a public offering price per share of $35.50, with expected gross proceeds of approximately $150.0 million. The offering also includes pre-funded warrants to purchase up to an aggregate of 1,056,725 shares of common stock at a purchase price of $35.4999 per pre-funded warrant. The underwriters have been granted a 30-day option to purchase up to 633,750 additional shares of common stock at the public offering price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced a proposed public offering of its common stock and prefunded warrants to purchase shares of common stock. The offering, subject to market conditions, is being made pursuant to a shelf registration statement filed with the SEC. The final terms will be disclosed in a final prospectus supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) provided an update on its portfolio and planned key milestones in 2024, including positive preliminary analysis of the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR), on-track enrollment for ulixacaltamide Phase 3 Studies, and a recently announced licensing partnership with Tenacia Biotechnology to develop and commercialize ulixacaltamide in Greater China with total consideration over $275 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.85%
Tags
none
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) announces a collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company, Ltd. for the development and commercialization of ulixacaltamide for the treatment of essential tremor in Greater China. Praxis will receive upfront proceeds of $15 million and is eligible to receive up to $264 million in milestone payments as well as tiered royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
Rhea-AI Summary
Praxis Precision Medicines (PRAX) will present new patient data and updates on clinical progress for its epilepsy programs at upcoming meetings in Orlando, Florida. The company aims to discuss its potential impact on patients and families with the epilepsy community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast through the company’s website. A replay of the webcast will be available for 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
conferences
Praxis Precision Medicines, Inc.

Nasdaq:PRAX

PRAX Rankings

PRAX Stock Data

776.53M
13.21M
0.17%
48.92%
3.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON

About PRAX

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res